


6 th Maudsley Mediterranean Forum

Palermo, 29 May 2019



UNIVERSITÀ DEGLI STUDI DI CATANIA
AZIENDA OSPEDALIERO UNIVERSITARIA
«Policlinico – Vittorio Emanuele»
CATTEDRA DI PSICHIATRIA



Defining the borders between
Borderline Personality disorder
and Bipolar disorder

Ludovico Mineo
Eugenio Aguglia

BORDERLINE PERSONALITY DISORDER: ORIGINS OF DIAGNOSIS



Adolph Stern
(1879-1958)

Adolph Stern recognized that a subgroup of his patients disregarded the usual boundaries of psychotherapy and did not fit into the existing classification system, a system concerned primarily with dividing psychoses from neuroses.

BORDERLINE GROUP OF PATIENTS CORE SYMPTOMS

Narcissism, psychic bleeding, inordinate hypersensitivity, psychic and body rigidity, negative therapeutic reactions, what looks like constitutionally rooted feelings of inferiority (deeply imbedded in the personality of the patient), masochism, what can be described as a state of deep organic insecurity or anxiety, the use of projection mechanisms, difficulties in reality testing (particularly in personal relationships)



FROM ORGANIZATION TO SYNDROME TO DISORDER

“not a transitory state fluctuating between neurosis and psychosis, but a stable personality organization ”



Otto Kernberg,
(1928 -)

Neurotic personality
organization

Psychotic personality
organization


Borderline personality
organization



Failed or weak identity formation, primitive defenses (namely, splitting and projective identification), and reality testing that transiently lapsed under stress.




Roy R. Grinker, Sr.
(1900-1993)



Borderline Syndrome Core Features

- Failures of self-identity
- Anaclitic relationships
- Depression based on loneliness
- Predominance of expressed anger.

FROM ORGANIZATION TO SYNDROME TO DISORDER



John G. Gunderson,
(1942 - 2019)



Discriminating Features of Borderline Patients



BY JOHN G. GUNDERSON, M.D., AND JONATHAN E. KOLB, M.D.

Am J Psychiatry 135:7, July 1978

CRITERIA FOR BORDERLINE PATIENTS

- **Low achievement**
- **Impulsivity**
- **Manipulative suicidal gestures**
- **Heightened affectivity**
- **Mild psychotic experiences**
- **High socialization (intolerance of being alone)**
- **Disturbed close relationships (de-evaluation , manipulation, dependency)**

DIAGNOSTIC CRITERIA DSM IV TR\DSM 5 FOR BORDERLINE PERSONALITY DISORDER



Affective criteria

- Inappropriate intense anger or difficulty controlling anger (eg, frequent displays of temper, constant anger, recurrent physical fights).
- Chronic feelings of emptiness.
- Affective instability that is due to marked reactivity of mood (eg, intense episodic dysphoria, irritability or anxiety usually lasting a few hours and only rarely more than a few days).

Cognitive criteria

- Transient, stress-related paranoid ideation or severe dissociative symptoms.
- Identity disturbance: notably and persistently unstable self-image or sense of self.

Behavioral Criteria (forms of impulsivity)

- Recurrent suicidal gestures, or threats or self-mutilating behaviour.
- Impulsivity in at least two areas that are potentially self-damaging (eg, spending, sex, substance misuse, reckless driving, binge eating).

Interpersonal criteria

- Frantic efforts to avoid real or imagined abandonment.
- A pattern of unstable and intense interpersonal relationships characterised by alternating between extremes of idealisation and devaluation.

DSM-V (American Psychiatric Association, 2013)

*"The typical clinical picture of borderline emerging from DSM-III and DSM-III-R describes an angry, depressed and impulsive patient, who, due to his mood instability, **can be considered not so much related to schizophrenia**, perhaps more so with **manic-depressive psychosis**. The features most typically considered close to schizophrenia (social isolation, suspiciousness, ideas of reference, inappropriateness, etc.) are in fact assigned to the diagnosis of schizotypal personality "*

WHO IS A BPD PATIENT?



Amy Winehouse
1983 - 2003

Self-Injury
Shame
Volatile relationships
Substance abuse
Impulsive
Suicidal
Eating disorder
Excessive anger

A clinical definition of "borderline pathology" should be articulated on three differentiated levels, the clinical one, psychosocial and relational.

On the clinical level: "the borderline patient shows one chronic disease, "stable in its instability" that takes the form of a Personality disorder, characterized by unstable and atypical mood symptoms, anxiety symptoms, impulse dyscontrol, dissociative or micropsychotic phenomena, complicated by the use of substances or other addictive behaviours, often as form of self-treatment

On the psychosocial level: "the borderline patient presents a problematic relationship compared to the concreteness of life, as shown by the partial or total incapacity to assume a role and a social and working identity, with consequent permanent project precariousness "

On a relational level: "borderline patients present a particular form of ambivalent attachment to caregivers and partners, characterized by the "impossible triad ": inability to be alone, inability to maintain stable relationships, intolerance of separations. However, despite the precariousness and the high level of conflict between their relationships, sometimes these also show a paradoxical depth and duration ("Neither with you nor without you")

6 th Maudsley Mediterranean Forum


Palermo, 29 May 2019



Defining the borders between
Borderline Personality disorder
and Bipolar disorder

**BORDERLINE PERSONALITY
DISORDER\BIPOLAR DISORDER
COMORBIDITY:**

REALITY OR ARTIFICE?



The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis

M. Fornaro^{a,*}, L. Orsolini^{b,c,d}, S. Marini^e, D. De Berardis^f, G. Perna^g, A. Valchera^d,
L. Ganança^{a,h}, M. Solmi^{i,j}, N. Veronese^k, B. Stubbs^{l,m}

M. Fornaro et al. / Journal of Affective Disorders 195 (2016) 105–118

42 papers (28 considering BPD in BD and 14 considering BD in BPD)

PREVALENCE OF BORDERLINE PERSONALITY DISORDER IN BIPOLAR DISORDERS:

26.1 % BDs

37,5 % Bd type II

Higher comorbid BPD in BD were noted in BD II participants (37.7%, 95% CI 21.9–56.6, studies= 6) and North American studies (26.2%, 95% CI 18.7– 35.3, studies=11)

PREVALENCE OF BIPOLAR DISORDER IN BORDERLINE PERSONALITY DISORDERS:

18.5% BDs

BD mixed was evident in 19.89% (95% CI 12.23–30.67) of people with BPD, which was higher than BD I (15.30%, 95% CI 6.47–32.06) and BD II (12.65%, 95% CI 4.79–29.47)

BORDERLINE, BIPOLAR OR BOTH?



MISDIAGNOSIS

Inability of current nosology to separate 2 distinct conditions


Bipolar disorder BPD

BPD exists on a spectrum with bipolar disorder

Bipolar I Bipolar II BPD



OVERLAPPING SYMPTOMS



CRITICISMS TO THE BORDERLINE PERSONALITY DISORDER CONSTRUCT.



Is BPD a personality disorder?

Studies conducted by well-known supporters of the conceptualization of BPD as a personality disorder have shown that **high rates of BPD patients undergo remission within the fourth decade of life**. Although this finding contradicts the very intrinsic definition of personality disorder, these same authors have not shown themselves opened to consider BPD as a **chronically fluctuating and relapsing affective disorder**, suggesting rather that the concept of personality disorder as life long disorder should be modified

Definitional inadequacies of BPD

The operational construct of BPD has a low discriminatory validity. **BPD has an unwieldy heterogeneity, overlapping not only with personality disorders within its own erratic cluster, but also with the odd and anxious clusters**. Moreover BPD criteria, rather than restricting themselves to defining personality attributes, **mix traits, symptoms and behaviors** -- particularly of an affective nature, accounting for the significant overlap of BPD with affective and addictive disorder.

Trivialization of Borderline personality organization

The operational construct of BPD has trivialized Kernberg's Borderline Personality Organization. **This latter is not a specific nosologic entity, but it describes a vulnerable psychic structure** that functions at a "stably unstable" level between the classic neuroses and psychoses, underpinning different personality dysfunctions .



Hagop Akiskal

Editorial

Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum

BPD symptoms are primarily affective: unstable, hostile, and labile moods - the unrelenting tension and irritability with superimposed paroxysms of rage – have been relegated by Gunderson and other authors into the characterologic realm. **Actually these are manifestations of a cyclothymic sensitive diathesis**

BPD patients are more likely to present a **higher familiarity for bipolar spectrum disorder than for schizophrenic spectrum, to have spontaneous and pharmacologic excursions into brief periods of elation, to receive an affective diagnosis at the follow up**

Beside the notion of hypomania as positive sunny euphoric traits and behaviour, there also exists **a more pervasive irritable-tempestuous side to bipolarity, the form most likely to arise from a cyclothymic baseline**, representing an unstable variant of bipolar II disorder that can be characterized as **"cyclothymic depression"**

The question of diagnostic overlap of BPD with other axis I disorders is **a fake issue**. Suffice it to say that such overlap pertains largely to anxiety, eating, addictive, and impulse control disorders, all of which **are well-known comorbid features of bipolar II**

"Psychoanalytic understanding and descriptive nosology are complimentary to one another. Affective reconceptualization of borderline pathology may substantially reduce the therapists' countertransference because now the patient is viewed **as affectively ill, rather than "character flawed or sociopathic**



Distinguishing bipolar disorder from borderline personality disorder: A study of current clinical practice

November 2015 Volume 30, Issue 8, Pages 965–974

K.E.A. Saunders, A.C. Bilderbeck, J. Price, G.M. Goodwin *

University Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX, United Kingdom


A qualitative study exploring how British NHS psychiatrists are confronted with the differential diagnosis between BPD\BD in their practical experience.

- **this differential diagnosis can be a source of disagreement amongst clinical staff;**
- **even if the majority of psychiatrists demonstrated a comprehensive understanding of the criteria recommended in DSM-IV-TR, many expressed the view that the diagnostic criteria did not necessarily assist diagnostic differentiation**
- **a quarter of respondents stated diagnostic criteria fail to correlate with the clinical phenomena in BPD and over a quarter of them (27%) expressed a preference for using an impressionistic approach rather than diagnostic criteria in diagnosing BPD**



BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

BORDERLINE
PERSONALITY
DISORDER



BIPOLAR
SPECTRUM
DISORDER

Onset and longitudinal course

Borderline personality disorder is generally partially structured by early adolescence, while onset of bipolar disorder generally occurs later (20 - 25 age)

Long-term outcome studies in bipolar disorder and BPD seem to challenge the traditional Axis I/Axis II dichotomy, in which mood disorders are widely thought of as episodic and treatable, whereas personality disorders are considered life-long and treatment refractory. **Many cases of bipolar disorder assume a chronic course, with long-term morbidity and substantial inter-episode symptomatology, whereas multiyear follow-up studies of patients with BPD have found that most people eventually stop meeting threshold criteria for the disorder**



BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

**BORDERLINE
PERSONALITY
DISORDER**



**BIPOLAR
SPECTRUM
DISORDER**

Mood swings and emotional dysregulation



In BPD, mood swings, usually of negative affect, are triggered by interpersonal stressors or perceived stressors, are transient, last from minutes to hours, and are highly dependent on the environment.

In bipolar disorder, mood swings are more spontaneous and of longer duration, especially for bipolar I disorder, and there are more extended periods of elation.

BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

BORDERLINE
PERSONALITY
DISORDER



BIPOLAR
SPECTRUM
DISORDER

Affective-emotional content

In distinguishing BPD from bipolar disorder II it is useful to look at different qualitative characteristics. **In type II BD, there is generally a shift from euthymia to hyperthymia with an increase in energy, productivity that appears to be prominent with respect to anger and irritability.** In the borderline a condition of real euthymia is generally absent, the euphoria is very rare.

In BD depressed mood is generally associated to the feeling of guilt, **while in BPD to the feeling of emptiness.**



BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

BORDERLINE
PERSONALITY
DISORDER



BIPOLAR
SPECTRUM
DISORDER




Self-identity

Borderline patients present a stable disruption to their sense of Self with core elements as painful incoherence, a role absorption, inconsistency and lack of commitment.

Bipolar patients may present Self-deficits only when depressed and a grandiose self when hypomanic, with stability of Self-identity when euthymic.

BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

BORDERLINE
PERSONALITY
DISORDER



BIPOLAR
SPECTRUM
DISORDER

Interpersonal relationships

By definition, **Borderline patients present a pattern of unstable and intense, turbulent interpersonal relationships. They are not able to see significant others as other than idealized, if gratifying, or devalued, if ungratifying.**



Cases of pure bipolar symptomatology do not show severe pathology of object relations during periods of normal functioning, and even chronic bipolar patients, maintain the capacity for relationships in depth, stability in their relations with others

BORDERLINE PERSONALITY DISORDER VS BIPOLAR DISORDER: PHENOMENOLOGICAL DIFFERENCES

**BORDERLINE
PERSONALITY
DISORDER**



**BIPOLAR
SPECTRUM
DISORDER**

Parasuicidal self-harm

Borderline patients present a two- fold increased risk of non lethal self-mutilating acts (50–80% of cases) ,frequently repetitive (41% of patients have more than 50 self-mutilation acts) compared to Bipolar patients.

Sexual abuse

A key course feature that potentially could differentiate bipolar illness from borderline personality is a history of sexual abuse. **In most recent metanalysis, 50–76% of patients with borderline personality disorder had experienced sexual trauma in childhood. In contrast, sexual abuse occurs in less than 30% of bipolar subjects**



Misdiagnosis of bipolar disorder as borderline personality disorder and viceversa: implication for treatment

Psychotherapies (in particular DBT) are central to the treatment for borderline personality

While many BPD patients are on polypharmacy regimes, with 4–5 drugs drawn from each major class (including antidepressants), psychotropic medication induce marginal symptomatic benefits



Bipolar I and bipolar II disorder always require medical management.

Lithium and anticonvulsant mood stabilizers are the drugs with the strongest support for both types in clinical trials.

Antidepressants should be used with caution when there is a suspicion of bipolar diathesis as they are known to cause treatment refractoriness and may contribute to suicidality

Psychotherapies alone are not effective in bipolar patients

6 th Maudsley Mediterranean Forum

Palermo, 29 May 2019



Defining the borders between
Borderline Personality disorder
and Bipolar disorder

**BIPOLAR AND COMORBID
BORDERLINE PERSONALITY
DISORDER: OUR EXPERIENCE**

IMPULSIVITY AND AGGRESSIVENESS IN BIPOLAR AND BORDERLINE PERSONALITY DISORDER

BPD

Stable core diagnostic feature

Prevalence of non planning impulsiveness over motor and attentional impulsiveness.

Preference for immediate gratification and discounting of delayed rewards underpins impulsive behaviors rather than emotional distress

Prospective predictor of suicidality and self-harm acts

Strict association with hostility



Psychological mediator of aggressive behavior



Bip.Dis

Both trait and state feature: more episodic course than in BPD but inter-episode impulsivity observed in euthymia

IN BDII , episode-based impulsivity is more commonly associated with hypomanic rather depressive BP II mood states

General prevalence of “attentional impulsiveness”.

Motor impulsiveness generally linked to mood-related behavioral disinhibition

Prospective predictor of severity of suicide attempts

Aggressiveness in DSM 5 criteria for Borderline Personality Disorder

Aggression against self

5. “**recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior**”

Aggression against others


8. “inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of temper, constant anger, **recurrent physical fights**)”



1st cause of hospitalization
9 % of patients die by suicide
58% have been involved occasionally or often' in physical fights as adults;
25% have used weapons against others

IMPULSIVE AGGRESSIVENESS

*Lack of behavioral inhibition and unconcern about consequences
Triggered by enviromental overstimulation and emotional distress*



IS BIPOLAR DISORDER SPECIFICALLY ASSOCIATED WITH AGGRESSION?

Lifetime Prevalence of “aggressive behaviours” in non-psychiatric sample: **0,66%**

Lifetime Prevalence of “aggressive behaviours” in Bipolar patients:

2,52% BDI 5,1 % BDII *


(HIGHER THAN IN MDD, PTSD, PSYCHOTIC DISORDERS, PANIC DISORDER)

Higher levels of aggressiveness compared to healthy subjects even in euthymic phase

Strict correlation with impulsivity levels: aggressive acts are largely of the impulsive type

More likely occurring in acute phase, manic hypomanic episode than in depression

Current Psychotic symptoms increase risk of aggressive acts



**IMPULSIVE
AGGRESSION**

**PSYCHOTIC
AGGRESSION**

*Pulay AJ, Dawson DA, Hasin DS, et al. Violent behavior and DSM-IV psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2008

Grunebaum et al., 2006; Najt et al., 2007; Látalová, 2009; Ballester et al., 2012

EFFECTS OF BIPOLAR DISORDER\BPD COMORBIDITY

**Bipolar
Disorder**



**Borderline
Personality
Disorder**

an earlier onset of BD (Goldberg et al., 2009; McDermid et al., 2015; Moor et al., 2012; Neves et al., 2009; Perugi et al., 2013)

Worse outcomes:

hospitalization (Colom et al., 2000), suicidal ideation and deliberate self-harm (Leverich et al., 2003), increased service utilization (Lembke et al., 2003), substance abuse (Kay et al., 2002), poor symptomatic outcome (George et al., 2003) and worse adherence and treatment response (Bieling et al., 2007; Colom et al., 2000)



Impulsivity and aggressiveness in bipolar disorder with co-morbid borderline personality disorder

Psychiatry Research 188 (2011) 40–44

Bernardo Carpiniello ^{a,*}, Lorena Lai ^a, Silvia Pirarba ^a, Claudia Sardu ^b, Federica Pinna ^a

IMPULSIVITY (BIS-11)

BD/BPD patients showed significantly higher mean scores with respect to BD and BD/OPD patients both on the Total Scale and the Attentional and Non-Planning subscales; mean scores on the Motor subscale were significantly higher in BD/BPD patients with respect to BD but not BD/OPD patients.

AGGRESSIVENESS (AQ)

BD/BPD patients showed significantly higher mean scores for the Total Scale and on the Physical Aggression and Hostility subscales with respect to BD but not BD/OPD patients; moreover, mean scores obtained by BD/BPD patients on the Verbal Aggressivity subscale were significantly higher than those in BD/OPD patients but not in BD patients.

TREATMENT OF BP DISORDERS WITH COMORBID BORDERLINE PERSONALITY DISORDER: AN UNDERINVESTIGATED FIELD

GUIDELINE RECOMMENDATION

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

J Psychopharmacol. 2016 June ; 30(6):

“Although the place of pharmacotherapy for borderline symptoms is based on limited evidence, the shared symptom of mood instability may be appropriately treated by medicines (e.g. lamotrigine, lithium, olanzapine, risperidone, aripiprazole and quetiapine) and borderline symptoms improved”

AVAILABLE STUDIES



THE JOURNAL OF CLINICAL PSYCHIATRY

Divalproex Sodium Treatment of Women With Borderline Personality Disorder and Bipolar II Disorder: A Double-Blind Placebo-Controlled Pilot Study

Frances R. Frankenburg and Mary C. Zanarini

Divalproex sodium proved to be superior to placebo in diminishing interpersonal sensitivity, irritability and anger/hostility

JOURNAL of AFFECTIVE DISORDERS

Journal of Affective Disorders 79 (2004) 297–303

Borderline personality disorder in patients with bipolar disorder and response to lamotrigine

Gilbert A. Preston*, Barrie K. Marchant, Fredrick W. Reimherr, Robert E. Strong, Dawson W. Hedges

Lamotrigine was effective in reducing borderline dimensions in bipolar I patients who qualified for a concomitant diagnosis of BPD after a retrospective evaluation

MEDICATION STRATEGIES FOR BORDERLINE PERSONALITY DISORDER SYMPTOMS

Drugs should not be used as primary therapy for borderline personality disorder, because they have only modest and inconsistent effects

The time-limited use of drugs can be considered as **an adjunct to psychological therapy, to manage specific symptoms.**

Patients with BPD should be informed that **there is no strong evidence base for the prescription of any drug'**

Cautious prescription of drugs that could be lethal in overdose or associated with substance misuse, because of **high suicide risk with prescribed drugs in people with borderline personality disorder**

The use of drugs can be considered **in acute crisis situations but should be withdrawn once the crisis is resolved**



Affective Dysregulation Symptoms	Impulsive Behavioural Symptoms	Cognitive Perceptual Symptoms
SSRI, SNRI	SSRI, SNRI	FGA
Antidepressants Tricyclics	Antidepressants Tricyclics	SGA
MAOI	FGA	
Benzodiazepines	SGA	
Mood Stabilizers Lithium Anticonvulsivants	Mood Stabilizers Lithium Anticonvulsivants	
Omega-3 fatty acids	Omega-3 fatty acids	

MANAGING IMPULSIVITY-AGGRESSIVENESS IN BORDERLINE PERSONALITY DISORDER: CURRENT EVIDENCES



IMPULSIVENESS, SELF MUTILATING BEHAVIOUR, SUICIDAL BEHAVIOUR

First generation antipsychotics

Haloperidol



Significant effect on **reduction of anger**

Flupentixole Decanoate



Large significant effect on reduction of **suicidal behaviour**

Second generation antipsychotics

Olanzapine



Significant effect on **reduction of anger**, unfavourable effect on **suicidality and self mutilating behaviour**

Aripiprazole



Large significant effect on **reduction of impulsivity and anger**; small significant effect on reduction of **self mutilating behaviour**

Ziprasidone

Mood stabilizers

Lamotrigine



Large significant effect on **reduction of impulsivity and anger**

Topiramate



Valproate



Large significant effect on **reduction of anger**, no effect on impulsivity and suicidality

Carbamazepine

Lithium

Antidepressants

Fluoxetine

Fluvoxamine

Phenelzine Sulfate

Omega-3 fatty acids



Slight significant effect on **suicidal ideation**

OPEN

Original article 121

Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study

Andrea Aguglia^{a,b}, Ludovico Mineo^c, Alessandro Rodolico^c,
Maria S. Signorelli^c and Eugenio Aguglia^c

Borderline personality disorder (BPD) often co-occurs with bipolar disorder (BD). Impulsivity and aggressiveness represent core shared features and their pharmacological management is mainly based on mood stabilizers and antipsychotics, although scarce evidence is available for this context of comorbidity. The aim of the present study was to evaluate the role of Asenapine as an adjunctive drug for reducing aggressiveness and impulsivity in a sample of Italian BD type I outpatients with or without a comorbid BPD. This was an observational 12-week open-label uncontrolled clinical study carried out from April to October 2014 in two psychiatric clinics in Sicily. Each patient was treated with asenapine at two dose options, 5 mg (twice daily) or 10 mg (twice daily), and concomitant ongoing medications were not discontinued. We measured impulsivity using the Barratt Impulsiveness Scale (BIS) and aggressiveness using the Aggressive Questionnaire (AQ). For the analysis of our outcomes, patients were divided into two groups: with or without comorbid BPD. Adjunctive therapy was associated with a significant decrease of BIS and AQ overall scores in the entire bipolar sample. Yet, there was no significant difference in BIS and AQ reductions between subgroups. Using a regression model, we observed that concomitant BPD played a negative role on the Hostility

subscale and overall AQ score variations; otherwise, borderline co-diagnosis was related positively to the reduction of physical aggression. According to our post-hoc analysis, global aggressiveness scores are less prone to decrease in patients with a dual diagnosis, whereas physical aggressiveness appears to be more responsive to the add-on therapy in patients with comorbidity. *Int Clin Psychopharmacol* 33:121–130 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.

International Clinical Psychopharmacology 2018, 33:121–130

Keywords: aggression, asenapine, bipolar disorder, borderline personality disorder, impulsivity, pharmacologic management


^aDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Section of Psychiatry, IRCCS Policlinico San Martino Hospital, Genoa, ^bRita Levi Montalcini Department of Neuroscience, University of Turin, Turin and ^cDepartment of Experimental and Clinical Medicine, Psychiatric Clinic University Hospital 'Gaspere Rodolico', University of Catania, Catania, Italy

Correspondence to Alessandro Rodolico, MD, Department of Experimental and Clinical Medicine, Psychiatric Clinic University Hospital 'Gaspere Rodolico', University of Catania, Via Santa Sofia, 78, Catania 95123, Italy
Tel/fax: +39 095 378 2470; e-mail: alessandro.rodolico@me.com

Received 25 June 2017 Accepted 31 October 2017



ASENAPINE



The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy

Rif S. El-Mallakh*, Courtney McKenzie

Medical Hypotheses 80 (2013) 530–533

Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, United States

Asenapine
Clozapine

$D4/D2 > 1$



Anti-aggression effect separated from antipsychotic effect due to D2 activation associated with reduced D4 activity.

In several RCT, clozapine has been shown to be superior to haloperidol, risperidone, and olanzapine in reducing aggression in psychotic patients

Asenapine is unique among antipsychotics in its sublingual administration, necessitated by its poor GI absorption

The most common side effects are sedation, orthostatic hypotension and oral hypoesthesia.

Lower propensity to cause weight gain, prolactin elevation, or QTc prolongation compared to most atypical antipsychotics. EPS rate similar to other SGA

Asenapine in the management of impulsivity and aggressiveness in Bipolar Disorder and comorbid Borderline personality disorder: an open label uncontrolled study



STUDY PROCEDURE

Observational, 12-weeks open-label uncontrolled clinical study, carried out from April to October 2014

Patients, aged between 18 and 65, with a previous diagnosis of Bipolar I Disorder in euthymic phase, with history of impulsive-aggressive behaviours, recruited into the A.O.U. Psichiatric Clinic "Policlinico Vittorio-Emanuele" of Catania

EXCLUSION CRITERIA



Neurological illness, a past or current schizophrenia spectrum disorder or other psychotic disorder; a past or current mental disorder due to a medical condition; current mental retardation or other significant neurocognitive disturbances; current severe physical illness; and concurrent alcohol and/or other substance abuse/dependence. Pregnant and sexually active women unwilling to use an effective means of contraception

PSYCHOPATHOLOGICAL ASSESSMENT:

Validation of BD type I diagnosis:

Structured Clinical Interview for DSM-IV (SCID- I)
Mood Disorder Questionnaire (MDQ)

BPD comorbidity

Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Borderline Syndrome Index (BSI)

*Levels of impulsiveness
and aggressiveness (V0 and V1):*

Italian version of the **Aggression Questionnaire (AQ)**
Italian version of the **Barratt Impulsiveness scale 11 (BIS-11)**

PHARMACOLOGICAL INTERVENTION:

12 Weeks period administration of Asenapine at flexible dose of 5 mg (BID) or 10 mg (BID) in addition to current medication

BASELINE DATA



	BD only (N=15)	BD and BPD (N=35)	Total (N=50)	P value (two-sided t-test)
SCID-II				
Mean (SD)	9.8 (1.82)	10.6 (1.67)	10.4 (1.74)	0.137
Median	10	11	11	
Minimum-maximum	5-13	7-13	5-13	
BSI				
Mean (SD)	16.2 (8.09)	37.9 (7.08)	31.4 (12.42)	<0.001*
Median	20	40	33	
Minimum-maximum	4-25	26-50	4-50	
MDQ [n (%)]				
Negative	6 (40.0)	2 (5.7)	8 (16.0)	0.002*
Positive	9 (60.0)	33 (94.3)	42 (84.0)	
AQ-PA				
Mean (SD)	23.7 (8.41)	29.5 (6.49)	27.8 (7.52)	0.012*
Median	23	32	30.5	
Minimum-maximum	13-36	14-43	13-43	
AQ-VA				
Mean (SD)	17.3 (7.48)	19.3 (3.83)	18.7 (5.20)	0.22
Median	19	20	20	
Minimum-maximum	5-28	10-28	5-28	
AQ-A				
Mean (SD)	21.5 (5.77)	25.6 (4.05)	24.4 (4.94)	0.007*
Median	21	27	25.5	
Minimum-maximum	13-32	14-34	13-34	
AQ-H				
Mean (SD)	21.2 (6.92)	27.0 (5.16)	25.3 (6.28)	0.002*
Median	20	28	25.5	
Minimum-maximum	8-31	18-35	8-35	
AQ-total				
Mean (SD)	83.8 (22.23)	101.4 (14.09)	96.1 (18.58)	0.001*
Median	89	104	101	
Minimum-maximum	43-114	66-129	43-129	
BIS				
Mean (SD)	67.2 (10.27)	69.2 (11.45)	68.6 (11.04)	0.563
Median	64	71	69	
Minimum-maximum	56-92	44-84	44-92	

BORDERLINE PERSONALITY COMORBIDITY

**50 BD type 1 patients; 15 (30%) pure;
BDP comorbidity= 35 (70%);**

IMPULSIVITY AND AGGRESSIVENESS LEVELS

BD/BPD : significantly higher mean scores for the Total Scale of AQ and on Physical Aggression and Hostility subscales in comparison to pure BD patients;
Levels of impulsivity between the two groups were instead found similar although a quantification of the three singular BIS subdimensions was not performed

AQ-A, Aggression Questionnaire-Anger; AQ-H, Aggression Questionnaire-Hostility; AQ-PA, Aggression Questionnaire-Physical Aggression; AQ-VA, Aggression Questionnaire-Verbal Aggression; BD, bipolar disorder; BIS, Barratt Impulsiveness scale; BPD, borderline personality disorder; BSI, Brief Symptom Inventory; MDQ, Mood Disorder Questionnaire; SCID-II, Structured Clinical Interview for DSM-IV Axis I Disorders.

*P value indicates significant.

RESULTS

Table 2 Impulsivity and aggression score variations: differences between BD and BD/BPD

	BD only (N=15)	BD and BPD (N=35)	P value (two-sided t-test)
ΔAQ-PA	-7.1 (7.72)	-7.0 (4.02)	0.962
ΔAQ-VA	-5.9 (5.08)	-4.3 (3.99)	0.287
ΔAQ-A	-4.8 (4.16)	-6.8 (3.94)	0.121
ΔAQ-H	-7.2 (6.98)	-7.2 (5.55)	1
ΔAQ	-24.9 (16.57)	-25.3 (11.37)	0.933
ΔBIS	-15.7 (11.06)	-13.6 (11.47)	0.544

AQ, Aggression Questionnaire; AQ-A, Aggression Questionnaire-Anger; AQ-H, Aggression Questionnaire-Hostility; AQ-PA, Aggression Questionnaire-Physical Aggression; AQ-VA, Aggression Questionnaire-Verbal Aggression; BD, bipolar disorder; BIS, Barratt Impulsiveness Scale; BPD, borderline personality disorder.

We recorded a significant decrease for each sub-dimensions of Aggressiveness (Physical, Verbal, Anger, Hostility) and for impulsivity, regardless of concomitant BPD. However, after controlling for confounding baseline factors, **the magnitude of variations were influenced by BPD co-diagnosis.**

After 12 weeks of administration, Asenapine has been proven to be effective in reducing impulsiveness (BIS score) and aggressiveness levels (AQ scores) in the total sample and in both subgroups of patients (pure BD and BD\BPD)

BPD



Positive correlation with Physical aggression score reduction

Higher ability of Asenapine in targeting neural mechanism related to physical aggressiveness



Negatively associated to total aggressiveness and hostility score



Side effects

No serious adverse effect was recorded and there was not any discontinuation of treatment. Nineteen (38%) patients reported increased somnolence\sedation, fourteen (28%) oral hypoesthesia, ten (20%) dysgeusia, 8 (16%) patients sporadic dizziness. No movement disorder was spontaneously reported or detected after clinical evaluation with dedicated scales. At V1 we didn't find any significant weight variation, $t(49) = 0.884$, $p=0.381$, two tails.

LIMITATIONS



Open-label study

Small simple size

Systematic clinical evaluation is missing

Role of concomitant medication was not analyzed and might affect asenapine response.

CLOSING REMARKS

A deeper phenomenological analysis of psychopathological domains, including impulsivity and aggression, can facilitate the differential diagnosis

An accurate clinical definition of comorbidity between BD and BPD is extremely important as the two conditions require different therapeutic modalities

Misdiagnosis can deprive the patient of potentially effective treatment or conversely lead to unnecessary and improper pharmacological prescription.

Given the burden of impulsivity and aggressiveness in the morbidity and mortality associated with these disorders, in the pharmacotherapy approach, clinicians should consider drugs able to specifically target these dimensions without jeopardizing other treatment outcomes



Thanks